Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.65 |
| ▸ | HTR1A | P08908 | 8/20 | 0.61 |
| ▸ | HTR7 | P34969 | 7/20 | 0.61 |
| ▸ | DRD2 | P14416 | 5/20 | 0.61 |
| ▸ | DRD4 | P21917 | 5/20 | 0.61 |
| ▸ | DRD3 | P35462 | 5/20 | 0.61 |
| ▸ | HTR2B | P41595 | 5/20 | 0.61 |
| ▸ | HRH1 | P35367 | 4/20 | 0.61 |
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.58 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402803 | 0.81 | OPRM1 (0.74) | HTR1AHTR7DRD2DRD4DRD3 | |
| SCHEMBL31060680 | 0.78 | PARP1 (1.00) | PARP1HTR1AHTR7PARP2 | |
| SCHEMBL6796265 | 0.78 | PARP1 (0.70) | PARP1HTR1AHTR7PARP2 | |
| SCHEMBL6795921 | 0.78 | PARP1 (0.70) | PARP1HTR1AHTR7PARP2 | |
| SCHEMBL11195725 | 0.77 | DRD2 (0.61) | HTR1AHTR7DRD2DRD4DRD3 | |
| SCHEMBL16256973 | 0.77 | OPRM1 (0.67) | HTR1AHTR7DRD2DRD4DRD3 | |
| SCHEMBL5296387 | 0.77 | OPRM1 (0.67) | HTR1AHTR7DRD2DRD4DRD3 | |
| SCHEMBL11669922 | 0.77 | OPRM1 (0.71) | HTR1AHTR7DRD2DRD4DRD3 | |
| SCHEMBL12946412 | 0.76 | PARP1 (0.67) | PARP1HTR1AHTR7PARP2 | |
| SCHEMBL6795086 | 0.76 | PARP1 (0.87) | PARP1HTR1AHTR7DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188103-B2 | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-29 | — | — | US | disclosed |
| US-20110077245-A1 | SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | VAN DER AA MARCEL JOZEF MARIA | 2011-03-31 | — | — | US | disclosed |
| US-7875621-B2 | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-25 | — | — | US | disclosed |
| US-7875621-B2 | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-25 | — | — | US | disclosed |
| US-20080176876-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | JANSSEN PHARMACEUTICA, NV (BE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176876-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | JANSSEN PHARMACEUTICA, NV (BE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176876-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | PARP1, PARP2, PARP3 | PARP1 1/4885HTR1A 1036/4885HTR7 2582/4885 |
| US-20110077245-A1 | SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885HTR1A 421/4885HTR7 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.